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Differences in SMA-like polymer architecture
dictate the conformational changes exhibited by
the membrane protein rhodopsin encapsulated in
lipid nano-particles†
Rachael L. Grime, ‡a,b Richard T. Logan,‡a Stephanie A. Nestorow,a Pooja Sridhar,a
Patricia C. Edwards, c Christopher G. Tate,c Bert Klumperman, d Tim R. Dafforn,a
David R. Poyner,e Philip J. Reeves*f and Mark Wheatley *g,b
Membrane proteins are of fundamental importance to cellular processes and nano-encapsulation strat-
egies that preserve their native lipid bilayer environment are particularly attractive for studying and exploit-
ing these proteins. Poly(styrene-co-maleic acid) (SMA) and related polymers poly(styrene-co-(N-(3-N’,N’-
dimethylaminopropyl)maleimide)) (SMI) and poly(diisobutylene-alt-maleic acid) (DIBMA) have revolutio-
nised the study of membrane proteins by spontaneously solubilising membrane proteins direct from cell
membranes within nanoscale discs of native bilayer called SMA lipid particles (SMALPs), SMILPs and
DIBMALPs respectively. This systematic study shows for the first time, that conformational changes of the
encapsulated protein are dictated by the solubilising polymer. The photoactivation pathway of rhodopsin
(Rho), a G-protein-coupled receptor (GPCR), comprises structurally-defined intermediates with charac-
teristic absorbance spectra that revealed conformational restrictions with styrene-containing SMA and
SMI, so that photoactivation proceeded only as far as metarhodopsin-I, absorbing at 478 nm, in a SMALP
or SMILP. In contrast, full attainment of metarhodopsin-II, absorbing at 382 nm, was observed in a
DIBMALP. Consequently, different intermediate states of Rho could be generated readily by simply
employing different SMA-like polymers. Dynamic light-scattering and analytical ultracentrifugation
revealed differences in size and thermostability between SMALP, SMILP and DIBMALP. Moreover, encap-
sulated Rho exhibited different stability in a SMALP, SMILP or DIBMALP. Overall, we establish that SMA, SMI
and DIBMA constitute a ‘toolkit’ of solubilising polymers, so that selection of the appropriate solubilising
polymer provides a spectrum of useful attributes for studying membrane proteins.
Introduction
Membrane proteins have evolved to function in the specialised
environment of a hydrated lipid bilayer membrane. This sub-
jects the embedded protein to lateral pressure and places it in
close association with lipids. Extracting membrane proteins
for study has until recently, universally required detergents.
However, the detergent micelle is often a poor mimic of the
native bilayer, lateral pressure is lost and annular lipids in
close proximity to the protein are stripped away, resulting in
conformational change and protein instability.1,2 In recent
years there has been a rapid increase in the use of detergent-
free methods for solubilising membrane proteins. Poly
(styrene-co-maleic acid) (SMA) spontaneously incorporates into
membranes and generates a nanoscale section of native mem-
brane as a disc (∼10 nm in diameter), referred to as a styrene
maleic acid lipid particle (SMALP), stabilised by a belt of
polymer and encapsulating membrane protein.3–8 SMALPs are
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proving to be a versatile platform for studying membrane pro-
teins, facilitating biophysical investigation9–11 plus structural
and functional studies,6,12–15 and with potential for high-
throughput screening in drug discovery following immobilis-
ation of SMALP-encapsulated therapeutic target proteins, such
as receptors, on surface plasmon resonance (SPR) chips.8 This
expanding utility of SMALPs has been the driver for developing
‘second generation’ SMA-like polymers, including poly(styrene-
co-(N-(3-N′,N′-dimethylaminopropyl)maleimide)) (SMI)16 and
poly(diisobutylene-alt-maleic acid) (DIBMA).17 In common
with SMA, both SMI and DIBMA directly solubilise cell mem-
branes to generate nanoscale lipid particles analogous to
SMALPs referred to as SMILPs and DIBMALPs respectively.16,18
Although progress has been made in characterising the differ-
ences in architecture and biophysical properties between
SMALPs, SMILPs and DIBMALPs,5,16–19 a fundamental ques-
tion that has not been addressed to-date, is whether the struc-
ture of the polymer stabilising the lipid particle affects the con-
formational changes of the membrane protein encapsulated
within it.
In this study, we report the first systematic investigation
into the effect of the polymer structure on the range of confor-
mational changes exhibited by a dynamic protein (rhodopsin,
the dim light receptor in the eye activated by light) when
encapsulated in a SMALP, SMILP or DIBMALP. Rhodopsin is a
G-protein-coupled receptor (GPCR). GPCRs are central to cell
signalling throughout the evolutionary tree from humans to
viruses (but not bacteria) and form the largest class of ‘chemi-
cal switches’ in biology. They transduce signals from chemical
messengers acting on a cell, such as hormones and neuro-
transmitters, into biochemical changes within the cell via acti-
vation of intracellular signalling cascades.20 As a result, they
regulate almost every physiological process. Consequently,
GPCRs form the largest family of membrane proteins in the
human genome (with >800 receptors) and are very important
to the pharmaceutical industry as they are the therapeutic
target of 30–40% of clinically-prescribed drugs.21,22 GPCRs
share a common protein architecture of a bundle of seven
transmembrane helices (TMs) and adopt a wide spectrum of
conformational states in executing their cell signalling role.23
Rhodopsin is an archetypical GPCR for which the intermediate
structures between the inactive and active states have been
defined in great detail.24 This makes rhodopsin an excellent
‘probe’ to investigate the effect of the chemical composition of
the stabilising polymer belt of structurally-related ‘SMALP-like’
lipid particles on the conformational changes of the encapsu-
lated membrane protein.
Our study establishes for the first time that the choice of
polymer used to solubilise a membrane protein dictates the
changes in conformation observed for the encapsulated
protein. Moreover, these different polymers effectively provide
a ‘toolkit’ that can be exploited by researchers to study
different conformational states and provide a range of stabi-
lities that expand the range of down-stream applications and
allow the investigator to tailor the properties of SMALP-like
lipid particle to their research needs.
Experimental
Preparation of rod outer segment (ROS) from bovine retina
Rhodopsin ROS was prepared from bovine retina by sucrose
density gradient centrifugation of ROS disc membranes, as
described previously.25 Bovine retinas were purchased from W.
L. Lawson Company Nebraska and stored frozen at −80 °C.
Retinas were defrosted and resuspended into buffer A (70 mM
K3PO4, 1 mM MgCl2, 5 mM BME, 0.1 mM PMSF, 30% sucrose,
pH 6.8) for ROS extraction. Homogenates were centrifuged at
4500g for 6 min at 4 °C. Pellets were re-extracted twice more
into buffer A. The pellet was then resuspended into buffer B
(70 mM K3PO4, 1 mM MgCl2, 5 mM BME, 0.1 mM PMSF, pH
6.8) and centrifuged at 50 000g for 20 min at 4 °C. The super-
natant was discarded and ROS pellets were pooled and resus-
pended into buffer C (70 mM K3PO4, 1 mM MgCl2, 5 mM
BME, 0.1 mM PMSF, 15% sucrose, pH 6.8). The suspension
was divided equally into centrifuge tubes, and under-laid with
buffer D (70 mM K3PO4, 1 mM MgCl2, 5 mM BME, 0.1 mM
PMSF, 0.64 M sucrose, pH 6.8), using a syringe and long
needle. The sample was centrifuged at 50 000g for 20 min at
4 °C. The supernatant was removed and pellets were resus-
pended and homogenised into buffer D (70 mM K3PO4, 1 mM
MgCl2, 5 mM BME, 0.1 mM PMSF, 0.64 M sucrose, pH 6.8).
Sucrose step gradients were then prepared in Ultra-clear tubes
(Beckman PA UZ-PA-38-5-1). Sucrose density gradients were
0.78 M, 1 M and 1.2 M in 70 mM K3PO4, 1 mM MgCl2, 5 mM
BME, 0.1 mM PMSF, pH 6.8. ROS was over-laid onto the gradi-
ent. Samples were centrifuged (with no brake) at 100 000g for
45 min at 4 °C. The ROS fraction was recovered by puncturing
the thin wall tube by the 0.78 M/1 M interface and aspirating
with an #18-gauge needle. The recovered ROS was diluted in
buffer B and centrifuged at 125 000g for 20 min at 4 °C. The
supernatant was discarded and resuspended and homogen-
ised into buffer B, then centrifuged again at 125 000g for
20 min at 4 °C. This wash step was performed twice. ROS
pellet was then resuspended and homogenized into buffer E
(50 mM Tris-HCl, 5 M urea, 5 mM EDTA, pH 7.4). The hom-
ogenate was incubated for 1 h, at 4 °C on an end-over-end
rotator. Following dilution into buffer F (50 mM Tris-HCl, pH
7.4) ROS membranes were centrifuged at 125 000g for 45 min
at 4 °C. The supernatant was removed and a series of three
repeated washes removed urea traces (resuspension in buffer
F, followed by centrifugation at 125 000g for 30 min at 4 °C).
The final ROS pellet was resuspended and homogenised into
buffer G (20 mM Tris-HCl, 2 mM EDTA, 10% sucrose, 1 mM
BME, 0.1 mM PMSF, pH 7.2). Aliquots were snap-frozen and
stored at −80 °C wrapped in foil.
Preparation of amphipathic copolymers
SMA was prepared from poly(styrene-co-maleic anhydride)
(SMAnh) (purchased from Cray Valley, UK) exactly as described
previously.7 For SMA preparation, a 10% (w/v) solution of
SMAnh was dissolved in 1 M NaOH and heated under reflux at
125 °C for 2–4 h, until the solution clarified. Solubilised SMA
was then precipitated by drop-wise addition of concentrated
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HCl and washed three times in ultrapure water. The SMA was
then re-dissolved in 0.6 M NaOH and wash steps repeated.
Finally, SMA was re-dissolved in 0.6 M NaOH, the pH adjusted
to pH 8.0 and lyophilised. SMI was prepared from SMA2000I
resin (purchased from Cray Valley, UK), exactly as described
previously.16 Briefly, for SMI preparation, concentrated HCl
was added dropwise to 10% (w/v) SMA2000I in ultra-pure water
to yield a 1 M solution. The solution was heated under reflux
at 125 °C for 2–4 h, until clarification. Solubilised SMI was
then precipitated by addition of 5 M NaOH to pH 9.0 and
washed three times in ultrapure water. The precipitated SMI
was then re-dissolved in a minimal volume of 0.6 M HCl, and
pH adjusted to pH 6.0 before lyophilisation. DIBMA was pre-
pared from Sokalan CP9. Briefly, 10 mL of Sokalan was
pipetted into 40 cm of dialysis tubing (1000 MWCO) and dia-
lysed for 24 h in dH20 water, with a water change at 12 h. A
second dialysis stage was then performed, for a further 24 h
(with water change at 12 h), with ∼200 mL solution being
placed into 80 cm fresh dialysis tubing (1000 MWCO). After
24 h, the solution was pH adjusted to pH 8.0, then frozen at
−80 °C for 48 h and subsequently lyophilised.
Solubilisation of ROS with SMA, SMI and DIBMA
ROS membranes preparations were thawed on ice and approxi-
mately 100 µg protein was added to relevant extraction buffers.
The DDM extraction buffer consisted of 1% (w/v) DDM in 1×
PBS, pH 7.8. The SMA extraction buffer consisted of 2.5% (w/v)
SMA in 1× PBS, pH 7.8. The SMI extraction buffer consisted of
2.5% (w/v) SMI in 1× PBS, pH 6.8. The DIBMA extraction buffer
consisted of 5% (w/v) DIBMA in 1× PBS, pH 7.8. Samples were
left on an end-over-end rotator for 1 h (room temperature)
before centrifugation at 100 000g, 1 h, 4 °C. Supernatant con-
taining solubilised rhodopsin was collected and stored at 4 °C.
Insoluble pellets were resuspended in an equal volume of 1×
PBS, and stored at 4 °C. Rhodopsin solubilisation efficiency
was determined using UV-visible absorption spectroscopy.
UV-visible absorption spectroscopy of rhodopsin and
photobleaching
UV-visible (UV-VIS) absorption spectroscopy was performed
using a Perkin-Elmer λ35 UV-VIS spectrophotometer equipped
with water-jacketed cell holder. All scans were performed at
20 °C, unless otherwise stated, and temperatures in the quartz
cuvettes were confirmed using a thermocouple probe (Omega
HH800A). Temperature was regulated with a water bath (Grant
LTCI GD120). A scan speed of 480 nm min−1 was set, as well as
a data interval of 2 nm bandwidth, with a response time of 1 s.
All spectra obtained were subject to normalisation to correct for
baseline-drift, whereby absorbance at 650 nm (A650) was cor-
rected to exactly zero. For photobleaching, all samples were illu-
minated directly in the spectrophotometer quartz cuvette using
a fibre-optic light guide (SCHOTT KL1500 Compact) fitted with
a >495 nm long-pass filter. Full dark-state spectra were obtained
before manually photobleaching the samples for 30 s intervals,
for up to 150 s. To determine solubilisation efficiency, quantitat-
ive yield was calculated based on the baseline corrected absor-
bance at 500 nm (A500). The molar extinction coefficient value
used for rhodopsin at 500 nm was 40 600 M−1 cm−1.26
Rhodopsin yields were then determined using The Beer–
Lambert Law (eqn (1)); where ε is molar extinction coefficient
(M−1 cm−1); c is concentration (M); and l is the path length (cm).
Molar concentration (c) was then converted to mass using eqn
(2) (relative formula mass of bovine rhodopsin = 39 010 dA).
c ¼ A500
ε  l ð1Þ
Mass ¼ cMr ð2Þ
Thermal stability of encapsulated rhodopsin
Thermal stability of rhodopsin encapsulated in a lipid particle
(Rho-LP; either SMALP, SMILP or DIBMALP) was determined
by monitoring A500 over time at the stated temperature. A500
was monitored via UV-VIS absorption spectroscopy as
described above. To determine the stability of the Rho-LP at
37 °C, the temperature regulating water bath was set to provide
an in-cuvette temperature of 37 °C. Cuvettes were pre-heated
prior to addition of Rho-LP sample and then allowed to equili-
brate in the spectrophotometer for 90 s, before the absorbance
spectrum was recorded between 650 nm and 250 nm. Spectra
were recorded every 30 min for a total of 960 min. Data were
then normalised to allow for plotting of relative A500 (%). A500
at 0 min was corrected to 100%, and 0% was set to the A500
value of the buffer blank. When the stability of the Rho-LP was
determined over a range of temperatures, the samples were
incubated at the stated temperatures for 30 min before the
UV-VIS absorption spectrum was recorded at 20 °C, as
described above.
Analytical ultracentrifugation (AUC)
Rho-LP samples were prepared for AUC in 137 mM NaCl,
2.7 mM KCl and 10 mM phosphate buffer, pH 7.4.
Experiments were performed using a Beckman Coulter
ProteomeLab XL-I Analytical Ultracentrifuge with a Ti50 rotor
at 20 °C, 40 000 rpm (129 000g). Absorbance at 280 nm was
monitored. Data were analysed using SEDFIT applying the con-
tinuous c(s) distribution model.27 Frictional ratio was per-
mitted to float.
Dynamic light scattering (DLS)
Dynamic light scattering (DLS) experiments were preformed
using a DynaPro Plate Reader III and DYNAMICS software
(Wyatt Technology, Haverhill, UK), using the laser wavelength
of 825.4 nm with a detector angle of 150°. Each sample (40 μL)
was loaded into a 384-well glass bottom SensoPlate™ (Greiner
Bio-One, Germany) in triplicate. Each measurement consisted
of 5 scans of 5 s. Scans were carried out initially at 25 °C, with
discrete 5 °C temperature increases, up to 60 °C. Each stepped-
increase in temperature was maintained for 30 min before DLS
data were collected to establish equilibrium. The attenuator
position and laser power automatically optimised for size (nm)
determination.
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The solubilising polymer dictates the range of conformational
changes in the encapsulated protein
SMA (Fig. 1a) revolutionised the study of membrane proteins,
by spontaneously solubilising membrane proteins within
nanoscale discs of native bilayer called SMALPs. ‘Second gene-
ration’ SMA-like polymers SMI and DIBMA retain the ability of
SMA to spontaneously solubilise membrane proteins but
exhibit different physico-chemical characteristics to SMA. SMI
possesses the styrene aromatic ring of SMA but is positively-
charged (Fig. 1b) and retains functionality at acidic pH, in con-
trast to the negative charge and alkaline working range of
SMA.16 DIBMA has the styrene aromatic ring of SMA replaced
by aliphatic diisobutylene but retains the maleic acid com-
ponent of SMA (Fig. 1c).17
In order to investigate the effect of the chemical compo-
sition of the polymer belt on the dynamic properties of the
encapsulated protein, we characterised photoactivation of rho-
dopsin encapsulated in a SMALP, SMILP or DIBMALP.
Activation of rhodopsin has been defined in great detail and
occurs via a series of specific intermediates.24 The photoreac-
tive chromophore of rhodopsin is 11-cis retinal covalently
bound to Lys296 by a protonated Schiff base. Absorption of a
photon of light induces rapid isomerisation of 11-cis retinal to
the all-trans configuration, a potent agonist. This drives the
conversion of dark-adapted inactive rhodopsin through a
series of structurally-defined intermediates, each with its
characteristic absorption maximum (λmax), to the fully-acti-
vated conformation metarhodopsin II (Meta II) which absorbs
at 382 nm (Fig. S1†).24 In addition to crystal structures of the
dark inactive rhodopsin and fully active Meta II, there are
crystal structures of the intermediate states bathorhodopsin,
lumirhodopsin and Meta I28–31 making rhodopsin the most
structurally-defined GPCR. These structures reveal that rho-
dopsin activation is not a gradual build-up of conformational
change, as there is relatively little change in the overall struc-
ture of light-activated rhodopsin as it transitions between the
photointermediates from the dark ground-state as far as Meta
I. In contrast however, conversion of Meta I to Meta II is
accompanied by a large conformational change at the cyto-
plasmic end of transmembrane helix-6 (TM6), which moves
out from the helical bundle, opening a binding crevice to
allow docking of the G-protein, transducin (Gt).
32,33 This large
outward movement of the cytoplasmic end of TM6 (by 7–14 Å)
is a characteristic feature of full activation of family A GPCRs
in general.23,34 This detailed knowledge of the structural and
spectroscopic features of the conformational states of rhodop-
sin during its photoactivation means that we can track the
sequential conformational changes from the inactive dark
state to the fully active Meta II conformation. Rhodopsin is
therefore an excellent ‘probe’ to investigate the effect of the
chemical composition of the stabilising polymer belt of a
‘SMALP-like’ lipid particle on the conformational changes of
the encapsulated membrane protein. Furthermore, using
bovine retina rhodopsin as the encapsulated membrane
protein allowed us to use the wild-type protein resident in rod
cell disc membranes and avoided the use of an engineered
recombinant construct with introduced reporter groups, or
structural changes, that might affect conformational changes.
Dark-adapted rhodopsin possesses a characteristic absorp-
tion peak (λmax) at 500 nm,
24 and this peak was clearly evident
when rhodopsin was solubilised by either the widely-used
detergent n-dodecyl-β-D-maltopyranoside (DDM) or by encapsu-
lation in one of the polymer-stabilised lipid particles (SMALP,
SMILP or DIBMALP) (Fig. 2a–d). The efficiency of solubil-
isation of rhodopsin was similar for DDM (1%), SMA (2.5%),
SMI (2.5%) and DIBMA (5%), where the number in the brack-
ets is the concentration used in each case. The extraction
efficiency values relative to DDM were 99 ± 5.5%, 97 ± 2.6%
and 98 ± 4.8% (mean ± s.e.m., n = 3) for SMA, SMI and DIBMA
respectively. Optimisation of rhodopsin solubilisation by
Fig. 1 Structurally-related polymers used to solubilise membrane proteins. (a) SMA, (b) SMI and (c) DIBMA.
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DIBMA (Table S1†) revealed that a slightly higher concen-
tration of DIBMA (5%) was required to generate the same
extraction efficiency as SMA (2.5%) and SMI (2.5%).
Photoactivation (30 s, hν > 495 nm) of the DDM-solubilised
rhodopsin generated the characteristic changes in the rhodop-
sin spectrum, with loss of the peak at 500 nm corresponding
to ground-state rhodopsin and appearance of a new absorption
peak (λmax) at 382 nm (Fig. 2a), consistent with the formation
of the fully-active rhodopsin conformation Meta II (Fig. S1†).24
Likewise, photoactivation of rhodopsin encapsulated in a
SMALP or SMILP caused a loss of the peak at 500 nm but in
contrast to DDM, generated a new absorption peak with λmax =
478 nm rather than 382 nm (Fig. 2b and c). This revealed that
photoconversion of rhodopsin in a SMALP or SMILP pro-
ceeded only as far as Meta I (λmax = 478 nm; Fig. S1†) but did
not progress further to the active Meta II conformation (λmax =
382 nm), even after an extended photobleaching period of 150
s (Fig. 2b and c). Both SMA and SMI contain styrene rings
which give absorption in the UV region (<300 nm) of the
spectrum.16,17 In marked contrast to SMALP or SMILP, photo-
activation of rhodopsin encapsulated in a DIBMALP pro-
gressed beyond Meta I to the active Meta II conformation (λmax
= 382 nm; Fig. 2d). The slight absorption observed >430 nm
may indicate the presence of low levels of residual photointer-
mediates. The slightly higher absorbance <400 nm in the dark-
state Rho-DIBMALP spectrum compared to Rho-SMALP and
Rho-SMILP, is probably due to greater light-scattering by the
larger DIBMALP.
The active conformation of rhodopsin can be stabilised by
occupation of the G-protein binding crevice on the cytoplasmic
side of the receptor. This can be achieved by incubation with a
small 11-mer peptide corresponding to the C-terminus
sequence of the α5 helix of the α-subunit of transducin,
referred to as G(t)-peptide35,36 or by formation of a rhodopsin:
Fig. 2 Spectra of dark-state and photoactivated rhodopsin in (a) DDM, (b) SMALP, (c) SMILP and (d) DIBMALP.
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34 Mini-G proteins comprise the guanosine
triphosphatase (GTPase) domain of the α-subunit of heterotri-
meric G-proteins and are fully capable of stabilising GPCRs in
their active state.37 Although full activation of rhodopsin to
Meta II was not observed in SMALP or SMILP, it was feasible
that rhodopsin in a SMALP or SMILP could transition ineffi-
ciently to Meta II but at levels too low to detect. To address
this, photoactivation was performed in the presence of Gt
peptide or mini-Go to trap any Meta II formed. However,
neither G(t)-peptide (500 µM) nor mini-Go (present in 500-fold
molar-excess) increased Meta II formation (Fig. S2†).
Therefore, it is highly unlikely that rhodopsin encapsulated in
a SMALP or SMILP can transition to the Meta II conformation.
It is noteworthy that the two polymers that prevented Meta II
formation (SMA and SMI) both possess a styrene aromatic ring
but when this is replaced by aliphatic diisobutylene in DIBMA
(Fig. 1) rhodopsin can transition to the active Meta II confor-
mation. It is known that the phenyl rings of the styrene moi-
eties in the polymer belt intercalate between the lipid acyl
chains perpendicular to the plane of the lipids,5 which can
affect the lipid packing order and the transition temperature
for gel to liquid phase transitions.17 This could have important
functional ramifications as membrane fluidity could impact
on the conformational flexibility of dynamic membrane pro-
teins like GPCRs, including rhodopsin. Interestingly, rhodop-
sin solubilised by the detergent digitonin also gets trapped at
Meta I upon activation possibly due to the digitonin micelle
forming a more rigid environment.38 In contrast, solubil-
isation by DIBMA has been shown to cause very little pertur-
bation to the packing and phase transition temperature of the
lipids.17 Furthermore, electron paramagnetic resonance spec-
troscopy and course-grained molecular dynamics simulations
revealed that the dynamics of lipids in a DIBMALP are less
constrained than in a SMALP and the affinity of spin-labelled
lipids for the polymer belt was more pronounced in a
SMALP.39 There are also differences in lipid transfer, which is
slower among DIBMALPs than among SMALPs.40 The current
study shows that although light-induced formation of Meta I
occurs within a SMALP or SMILP environment, there is some
degree of conformational restriction endowed by the nature of
the copolymer belt that prevents the full activation of rhodop-
sin to Meta II observed within a DIBMALP. The suggestion that
the copolymer component of a SMALP or SMILP can restrict
the range of conformational transitions adopted by the encap-
sulated protein, either directly or via changes in lipid packing
and dynamics, is supported by recent studies on the human
adenosine A2A receptor (A2AR) and the photoreceptor/transdu-
cer complex (NpSRII2/NpHtrII2) from Natronomonas
pharaonisfrom.11,41 Stimulation of A2AR in a SMALP by the
agonist NECA generated only small conformational changes11
and the conformational freedom of NpSRII2/NpHtrII2 was also
restricted in a SMALP.41 Interestingly, NpSRII2 could be fully
activated when encapsulated in a DIBMALP.42
Characterisation of Rho-SMALP, Rho-SMILP and Rho-
DIBMALP
The characteristics of the rhodopsin lipid particles (Rho-LPs)
were investigated further. Rhodopsin encapsulated in a
SMALP, SMILP and DIBMALP (Rho-SMALP, Rho-SMILP, Rho-
DIBMALP respectively) was analysed by dynamic light scatter-
ing (DLS) to determine the hydrodynamic diameter of the par-
ticles (Fig. 3a–c). The size of Rho-SMALP and Rho-SMILP were
similar with z-average diameters of 9.9 ± 0.2 nm, and 8.7 ±
0.3 nm (mean ± s.e.m., n = 3) respectively, consistent with pre-
viously published values of ∼10 nm diameter.3,5,16,43 The Rho-
DIBMALP was larger, with a z-average diameter of 18.9 ±
2.9 nm (mean ± s.e.m., n = 3) which is also in agreement with
published values.17,44 It is possible that the larger diameter of
the DIBMALP compared to the SMALP and SMILP contributes
to its ability to support transition to Meta II, as computational
simulations of lipid dynamics in empty ‘lipid only’ discs indi-
cated a stiffening of the lipids due to a confinement effect of
the disc but this stiffening was lower when the disc diameter
was increased from 9.8 nm to 18.4 nm.45 The thermostability
of the Rho-LPs was determined using DLS in combination
with increasing the temperature by 5 °C intervals from 25 °C
up to a maximum of 60 °C. Clear differences were observed
between the different lipid particles (Fig. 4). Rho-SMALP was
the least stable, with a loss of DLS signal >40 °C suggesting
breakdown of the Rho-SMALP at these higher temperatures. In
contrast, both Rho-SMILP and Rho-DIBMALP were stable over
the temperature range tested. An apparent increase in the
z-average diameter of Rho-SMILP from 8.7 ± 0.3 nm to 15.0 ±
0.9 nm (mean ± s.e.m., n = 3) was noted >50 °C (Fig. 4). It can
be speculated that this represents interaction between individ-
ual Rho-SMILPs at the higher temperatures.
Fig. 3 Size of the Rho-LPs determined by DLS. A representative experiment is shown for (a) Rho-SMALP, (b) Rho-SMILP and (c) Rho-DIBMALP.
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In the current study, encapsulation in a DIBMALP provided
rhodopsin with a greater degree of thermostability than in a
SMALP (Fig. 6a and b). However, it appears that there are
protein-specific differences with respect to the comparative
stability of proteins encapsulated in a SMALP versus a
DIBMALP. For example, the thermostability of the human sero-
tonin transporter (hSERT) is comparable in a SMALP or a
DIBMALP but the A2AR in a DIBMALP was reported to be less
stable to long-term storage (6 days) at 4 °C than in a
SMALP.44,46
Rho-LP were characterised further using sedimentation vel-
ocity analytical ultracentrifugation (AUC; Fig. 5). The data were
analysed using the continuous c(s) analysis method to deter-
mine sedimentation coefficients and molar masses, using the
SEDFIT software and the method of Schuck.27 The large peak
in each trace, with sedimentation coefficients of ∼1.5S (Rho-
SMALP; Fig. 5a), ∼2S (Rho-SMILP; Fig. 5b) and 3S (Rho-
DIBMALP; Fig. 5c) respectively, is likely to be free polymer and
polymer aggregates. The second peak in each trace is compati-
ble with the known sizes of the Rho-LPs. The sedimentation
coefficient of 4.6S for Rho-SMALP is consistent with a molar
mass of ∼89 kDa. It has been determined previously that the
SMA polymer and lipid of a SMALP contribute ∼35 kDa of a
∼70 kDa SMALP encapsulating the protein ZipA.7 This would
imply that the Rho component of Rho-SMALP is ∼54 kDa.
Given that the mass of Rho, including the post-translational
modifications (two glycosylation sites plus two palmitoylation
sites) is ∼43 kDa,47 this would indicate that the encapsulated
Rho was a monomer and not a dimer (∼86 kDa) or higher oli-
gomer. This is relevant as although it is known that a single
light-activated Rho is sufficient to activate its G-protein trans-
ducin,48 in native rod outer segment membranes Rho can
organise into rows of dimers.49,50 The fact that monomeric
Rho and not Rho dimers were encapsulated in the SMALP
might be a ramification of the precise molecular mechanisms
by which SMA monomers are incorporated into the membrane
and polymerise to excise the SMALPs. What is clear, is that
encapsulation of Rho monomers was not due to there being
insufficient space within a SMALP to accommodate the
14-transmembrane helices (TMs) of a rhodopsin dimer, as
Alternative Complex III in a functional super-complex with
cytochrome oxidase was isolated encapsulated within a SMALP
despite having a total of 48-TMs.12 The DLS experiments pre-
sented earlier in this study highlighted that Rho-SMALP and
Rho-SMILP were of similar size. AUC revealed that Rho-SMILP
had a sedimentation coefficient 4.1S consistent with a molar
mass of ∼87 kDa. Lipid-only ‘empty’ SMILP containing only
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC-SMILP)
without encapsulated protein gave a single major peak (2.35 S,
Fig. S3†) consistent with a molar mass of 56 kDa, with a minor
component at ∼5S. This is 31 kDa less than the Rho-SMILP,
suggesting encapsulation of a single Rho (∼43 kDa), like Rho-
SMALP, and not a dimer (∼86 kDa). DLS revealed that Rho-
DIBMALP is larger than either Rho-SMALP or Rho-SMILP and
this was apparent in the AUC as Rho-DIBMALP had a sedimen-
tation coefficient of 5.2 S and a predicted molar mass of
117 kDa. Lipid-only ‘empty’ DIBMALP (DMPC-DIBMALP) gave
a single major AUC peak (3.35 S, Fig. S3†) consistent with a
molar mass of 65 kDa, with a minor component at ∼5S. This is
52 kDa less than the Rho-DIBMALP, again suggesting encapsu-
lation of a Rho monomer (∼43 kDa) and not a dimer
(∼86 kDa). In addition to investigating the effect of tempera-
ture on the lipid particles (Fig. 4), the thermostability of the
encapsulated protein within each Rho-LP was also compared.
Each Rho-LP was incubated at a range of temperatures
between 4 °C–60 °C, using 5 °C increments, and the thermal
stability of Rho was determined by the decrease in absorbance
at 500 nm which represents the release of the 11-cis-retinal
Fig. 5 Sedimentation velocity AUC analysis of Rho-LPs. A representative AUC experiment is shown for (a) Rho-SMALP, (b) Rho-SMILP and (c) Rho-
DIBMALP.
Fig. 4 Temperature-dependent changes in Rho-LP diameter deter-
mined by DLS, for Rho-SMALP ( ), Rho-SMILP ( ) and Rho-DIBMALP
( ). Data are mean ± s.e.m. (n = 3).
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chromophore (Fig. 6a). The Rho within a Rho-SMALP was the
least thermostable with a T50 = 45.7 ± 0.5 °C (mean ± s.e.m., n
= 3). Encapsulation of Rho in DIBMALP conferred an increase
in Rho thermostability of 6 °C (T50 = 51.4 ± 0.8 °C mean ± s.e.
m., n = 3) compared to Rho-SMALP (Fig. 6a). The lower ther-
mostability of Rho in a SMALP compared to a DIBMALP may
reflect the lower thermostability of the SMALP particle com-
pared to the DIBMALP particle (Fig. 4). Rho was also more
thermostable in a SMILP than a SMALP (Fig. 6a), although T50
= >50 °C, a precise T50 value could not be determined for Rho-
SMILP as above 55 °C a slight precipitate formed which pre-
vented data collection at higher temperatures. The rate of
thermal decay of Rho was determined at 37 °C for each Rho-LP
using a pre-heated spectrophotometer and monitoring absor-
bance at 500 nm for 16 h (Fig. 6b). Consistent with data pre-
sented above, the Rho encapsulated in a SMALP was the least
thermostable at 37 °C (Rho-SMALP; t1/2 = 183 ± 5 min; mean ±
s.e.m. (n = 3)). In contrast, Rho within a SMILP or a DIBMALP
showed no thermal decay over the 16 h period. It is noteworthy
that the rate of Rho decay in the Rho-SMALP at 37 °C was very
similar to the loss of ligand binding capability of another
GPCR, the human adenosine A2A receptor (A2AR) encapsulated
in a SMALP incubated at 37 °C (A2AR-SMALP; t1/2 = 148 ±
13 min; mean ± s.e.m. (n = 3)).6 As an extreme test of stability,
the effect of lyophilisation on Rho-LPs was quantified using
absorbance at 500 nm to assess Rho decay following lyophilisa-
tion and re-hydration with buffer (Fig. 6c). Despite such harsh
treatment, ∼50% of the Rho encapsulated in a SMALP or
DIBMALP was recovered with the chromophore intact (54 ± 3%
and 48 ± 7% respectively, mean ± s.e.m. (n = 3)). However, Rho
encapsulated in SMILP was even more stable and was
unaffected by lyophilisation (recovery 106 ± 2%, mean ± s.e.m.,
n = 3; Fig. 6c). The availability of such a stable storage form of
a membrane protein as a lyophilised SMILP could be a useful
resource not only for storage but as a reagent for downstream
applications.
Defining the characteristics of Rho, a native GPCR, encap-
sulated by three different but structurally-related polymers
(Rho-SMALP, Rho-SMILP and Rho-DIBMALP) enabled direct
comparisons to be made. SMALP and SMILP allowed confor-
mational change in light-activated Rho as far as Meta I but the
effect of the styrene ring in these polymers, or constraints due
to their smaller size, prevented complete photoconversion of
Rho to the fully-active Meta II observed in Rho-DIBMALP.
Consequently, SMALP and SMILP, both of which prevented full
activation of Rho, might facilitate structural studies on confor-
mational intermediates or drug discovery programmes where
stabilisation of an inactive or partially-active intermediate
receptor conformation is required. In contrast,
GPCR-DIBMALP may provide a better platform for a screen in
a discovery programme for a drug that fully activates the recep-
tor. It would be important nevertheless, to confirm the confor-
mational sub-state of individual GPCRs solubilised by SMA,
SMI or DIBMA and not assume that all GPCRs behave exactly
like rhodopsin. Furthermore, not all important GPCR confor-
mational states will be accessible to investigation simply
through choice of solubilising polymer alone.
Conclusions
Nanodisc technology is becoming widely adopted as a strategy
for solubilising membrane proteins due to the benefits pro-
vided over other solubilisation approaches. The direct solubil-
isation of proteins from membranes by SMALPs with the pres-
ervation of the native environment including annular lipids,
has driven the generation of new SMA-like polymers resulting
in SMILPs and DIBMALPs.
This study shows for the first time, that the dynamic range
of conformational changes exhibited by a membrane protein
encapsulated in a nanoscale lipid-particle is dictated by the
chemical composition of the stabilising polymer employed to
generate the nanoparticle. Using Rho, a member of the large
GPCR family of membrane proteins that constitute the
primary therapeutic target in drug discovery,21 we establish
that SMA, SMI and DIBMA provide a ‘toolkit’ of solubilising
polymers. Selection of the appropriate solubilising polymer
provides a spectrum of useful attributes for studying mem-
Fig. 6 Stability of the encapsulated Rho in Rho-LPs. The decay of Rho encapsulated in SMALP (blue), SMILP (red) or DIBMALP (green) was moni-
tored by decrease in absorbance at 500 nm. (a) Thermostability was assessed after incubating the Rho-LPs for 30 min at the temperatures indicated.
(b) Thermostability at 37 °C. (c) Recovery following lyophilisation and rehydration. Data are mean ± s.e.m. (n = 3) in each case.
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brane proteins, including generation of specific intermediate
states and differences in thermostability of the encapsulated
protein. This new insight into the expanded utility of the SMA-
like polymers will have practical benefits for researchers study-
ing membrane proteins using a wide range of approaches.
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